Search
Selamectin
go.drugbank.com/drugs/DB11459ExperimentalVet approvedIt is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin. Selamectin is not approved for human use. … Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well
Mandelic acid
go.drugbank.com/drugs/DB13218ApprovedMandelic acid is an approved aromatic, alpha hydroxy acid . Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCarmofur
go.drugbank.com/drugs/DB09010ApprovedWithdrawnCarmofur has been known to induce leukoencephalopathy.
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
go.drugbank.com/drugs/DB16029Investigational2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).
Fonadelpar
go.drugbank.com/drugs/DB16169InvestigationalFonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).
Amubarvimab
go.drugbank.com/drugs/DB16493InvestigationalAmubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
Categories: Experimental Unapproved Treatments for COVID-19Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
SR 140333
go.drugbank.com/drugs/DB05790ExperimentalSR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
Categories: Experimental Unapproved Treatments for COVID-19Urethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.